Methylphenidate Use for Emotional Dysregulation in Children and Adolescents with ADHD and ADHD and ASD: A Naturalistic Study
Open accessThe DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Abstract
Emotional dysregulation (ED) is common in attention-deficit/hyperactivity disorder (ADHD). Nonetheless, research on ADHD in children with autism spectrum disorder (ASD) and ADHD is still ongoing. Several studies suggest that methylphenidate (MPH) may be effective for ED in ADHD, while there is not enough evidence about its use in ASD with comorbid ADHD. This naturalistic study aims to investigate the effectiveness of immediate- and extended-release MPH in the treatment of ED in 70 children and adolescents (6–18 years), with a diagnosis of ADHD (n = 41) and of ASD with comorbid ADHD (n = 29), using the Child Behavior Checklist—Attention/Aggressive/Anxious (CBCL-AAA). Their parents completed the CBCL twice—first during the summer medication-free period, that is, at least one month after drug interruption; and again after three months of treatment restart. Results demonstrate that MPH is associated with a statistically significant reduction in ED in ADHD and ASD, without substantial adverse events, supporting the use of psychostimulants for the treatment of ED in these neurodevelopmental disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Karalunas, S. L., Fair, D., Musser, E. D., Aykes, K., Iyer, S. P., & Nigg, J. T. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.763 · Cited by 340
RetractedDiagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Baio, J., Wiggins, L., Christensen, D. L., Maenner, M. J., Daniels, J., Warren, Z., Kurzius-Spencer, M., Zahorodny, W., Robinson, C., Rosenberg, et al. (2018) · MMWR. Surveillance Summaries · doi:10.15585/mmwr.ss6706a1 · Cited by 6,078
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.942 · Cited by 5,346
Conners, C. K., Sitarenios, G., Parker, J. D. A., & Epstein, J. N. (1998) · Journal of Abnormal Child Psychology · doi:10.1023/a:1022602400621 · Cited by 1,772 · cited 1×
“Diagnosis was also supported by standardized diagnostic tools, specific for ADHD and ASD: the Revised Conners’ Parent Rating Scale (CPRS-R) [39], the Autism Diagnostic Observational Schedule, Second Edition (ADOS-2) [40,41], the Autism Diagnostic Interview-Revised (ADI-R) [42] and the Autism Spectrum Diagnostic Interv…”
MethodAutism Diagnostic Interview-Revised
Rutter, M., LeCouteur, A., & Lord, C. (2016) · PsycTESTS Dataset · doi:10.1037/t18128-000 · Cited by 1,627
Emotion Dysregulation in Attention Deficit Hyperactivity Disorder
Shaw, P., Stringaris, A., Nigg, J., & Leibenluft, E. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070966 · Cited by 1,232 · cited 1×
“Individuals with ADHD combined with ED were more impaired in global functioning [20].”
ADHD in Children and Young People: Prevalence, Care Pathways, and Service Provision
Sayal, K., Prasad, V., Daley, D., Ford, T., & Coghill, D. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30167-0 · Cited by 1,223
Danielson, M. L., Bitsko, R. H., Ghandour, R. M., Holbrook, J. R., Kogan, M. D., & Blumberg, S. J. (2018) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2017.1417860 · Cited by 1,181
Autism Spectrum Disorder: Classification, diagnosis and therapy
Sharma, S. R., Gonda, X., & Tarazi, F. I. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.007 · Cited by 673
(2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1266 · Cited by 521
Barkley, R. A., & Fischer, M. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.01.019 · Cited by 479
Barkley, R. A., & Fischer, M. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-201005000-00011 · Cited by 479
Faraone, S. V., Rostain, A. L., Blader, J., Busch, B., Childress, A. C., Connor, D. F., & Newcorn, J. H. (2019) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12899 · Cited by 400 · cited 1×
“These symptoms are more prevalent in the ADHD combined subtype, especially when comorbid with oppositional defiant disorder [19], and their severity increases with the severity of other ADHD symptoms [4].”
BackgroundSobanski, E., Banaschewski, T., Asherson, P., Buitelaar, J., Chen, W., Franke, B., Holtmann, M., Krumm, B., Sergeant, J., Sonuga‐Barke, E., et al. (2010) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2010.02217.x · Cited by 365
Three dimensions of oppositionality in youth
Stringaris, A., & Goodman, R. (2009) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2008.01989.x · Cited by 363 · cited 1×
“These symptoms are more prevalent in the ADHD combined subtype, especially when comorbid with oppositional defiant disorder [19], and their severity increases with the severity of other ADHD symptoms [4].”
BackgroundEmotion regulation in autism spectrum disorder: Where we are and where we need to go
Cai, R. Y., Richdale, A. L., Uljarević, M., Dissanayake, C., & Samson, A. C. (2018) · Autism Research · doi:10.1002/aur.1968 · Cited by 347
Christensen, D. L., Maenner, M. J., Bilder, D., Constantino, J. N., Daniels, J., Durkin, M. S., Fitzgerald, R. T., Kurzius-Spencer, M., Pettygrove, S. D., Robinson, C., et al. (2019) · MMWR. Surveillance Summaries · doi:10.15585/mmwr.ss6802a1 · Cited by 344
Emotion dysregulation and the Core features of autism Spectrum disorder
Samson, A. C., Phillips, J. M., Parker, K. J., Shah, S., Gross, J. J., & Hardan, A. Y. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-2022-5 · Cited by 338 · cited 1×
“Several studies analyzed the prevalence of ED both in ADHD, finding percentages between 24 and 55% in children and adolescents and 34 to 70% in adults [3,13], and in ASD, finding a percentage between 50% and 82% [5,24,25].”
BackgroundWechsler Preschool and Primary Scale of Intelligence--Third Edition
Wechsler, D. (2012) · PsycTESTS Dataset · doi:10.1037/t15177-000 · Cited by 331
Mazefsky, C. A., & White, S. W. (2014) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2013.07.002 · Cited by 323
Affect regulation and temperament in children with autism spectrum disorder
Konstantareas, M. M., & Stewart, K. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-005-0051-4 · Cited by 307
Gillberg, C., Gillberg, C., Råstam, M., & Wentz, E. (2001) · Autism · doi:10.1177/1362361301005001006 · Cited by 298 · cited 1×
“Diagnosis was also supported by standardized diagnostic tools, specific for ADHD and ASD: the Revised Conners’ Parent Rating Scale (CPRS-R) [39], the Autism Diagnostic Observational Schedule, Second Edition (ADOS-2) [40,41], the Autism Diagnostic Interview-Revised (ADI-R) [42] and the Autism Spectrum Diagnostic Interv…”
MethodSelf-Regulation of Emotion, Functional Impairment, and Comorbidity Among ChildrenWith AD/HD
Anastopoulos, A. D., Smith, T. F., Garrett, M. E., Morrissey-Kane, E., Schatz, N. K., Sommer, J. L., Kollins, S. H., & Ashley-Koch, A. (2011) · Journal of Attention Disorders · doi:10.1177/1087054710370567 · Cited by 269
Skirrow, C., & Asherson, P. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.10.011 · Cited by 230
Irritability in children and adolescents: a challenge for DSM-5
Stringaris, A. (2011) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-010-0150-4 · Cited by 214 · cited 1×
“Individuals with ADHD often present excessive and rapidly shifting emotions, associated with irritable and aggressive behavior [9], susceptibility to anger and low tolerance for distress [10–18].”
BackgroundCastells, X., Ramos-Quiroga, J. A., Rigau, D., Bosch, R., Nogueira, M., Vidal, X., & Casas, M. (2011) · CNS Drugs · doi:10.2165/11539440-000000000-00000 · Cited by 197
An update on pharmacotherapy of autism spectrum disorder in children and adolescents
Goel, R., Hong, J. S., Findling, R. L., & Ji, N. Y. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1458706 · Cited by 176
Pringsheim, T., Hirsch, L., Gardner, D., & Gorman, D. A. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506000202 · Cited by 163 · cited 1×
“To date, not many studies have investigated the efficacy and safety of MPH in ADHD patients with comorbid disorders, albeit preliminary data demonstrated MPH efficacy on oppositional, aggressive and antisocial behaviors, on mood lability, and on obsessive and compulsive symptoms [28,53,54].”
BackgroundLeiter International Performance Scale-Revised (Leiter-R)
Farmer, C. (2021) · Springer eBooks · doi:10.1007/978-3-319-91280-6_1643 · Cited by 150
Lenzi, F., Cortese, S., Harris, J., & Masi, G. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.08.010 · Cited by 141 · cited 1×
“There have been far few studies investigating the efficacy and safety of MPH in those with ADHD and co-existing disorders: some studies concluded that MPH remains effective at reducing ADHD symptoms in the presence of affective comorbidities, without an effect on comorbid conditions (anxiety, depression [36]); other s…”
BackgroundBiederman, J., Petty, C. R., Day, H., Goldin, R. L., Spencer, T., Faraone, S. V., Surman, C. B. H., & Wozniak, J. (2012) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e3182475267 · Cited by 135
Surman, C. B. H., Biederman, J., Spencer, T., Yorks, D., Miller, C. A., Petty, C. R., & Faraone, S. V. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10081172 · Cited by 135
Methylphenidate for children and adolescents with autism spectrum disorder
Sturman, N., Deckx, L., & van Driel, M. L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011144.pub2 · Cited by 135 · cited 1×
“Previous review studies comparing MPH to placebo in children with ASD [62,68] globally show that it was mildly superior for inattention, irritability and stereotypes, and did not worsen the core symptoms of ASD.”
BackgroundReichow, B., Volkmar, F. R., & Bloch, M. H. (2013) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1793-z · Cited by 134 · cited 2×
“Previous review studies comparing MPH to placebo in children with ASD [62,68] globally show that it was mildly superior for inattention, irritability and stereotypes, and did not worsen the core symptoms of ASD.”
BackgroundBiederman, J., Spencer, Petty, O'Connor, Hyder, Surman, & Faraone (2012) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s29670 · Cited by 134 · cited 1×
“Several studies analyzed the prevalence of ED both in ADHD, finding percentages between 24 and 55% in children and adolescents and 34 to 70% in adults [3,13], and in ASD, finding a percentage between 50% and 82% [5,24,25].”
BackgroundRösler, M., Retz, W., Fischer, R., Ose, C., Alm, B., Deckert, J., Philipsen, A., Herpertz, S., & Ammer, R. (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622971003624197 · Cited by 131
Asherson, P., Young, A. H., Eich-Höchli, D., Moran, P., Porsdal, V., & Deberdt, W. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.915800 · Cited by 130
Spencer, T. J., Faraone, S. V., Surman, C. B. H., Petty, C., Clarke, A., Batchelder, H., Wozniak, J., & Biederman, J. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.09.2459 · Cited by 127
Fernández de la Cruz, L., Simonoff, E., McGough, J. J., Halperin, J. M., Arnold, L. E., & Stringaris, A. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.10.006 · Cited by 120
Pringsheim, T., Hirsch, L., Gardner, D., & Gorman, D. A. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506000203 · Cited by 116 · cited 1×
“To date, not many studies have investigated the efficacy and safety of MPH in ADHD patients with comorbid disorders, albeit preliminary data demonstrated MPH efficacy on oppositional, aggressive and antisocial behaviors, on mood lability, and on obsessive and compulsive symptoms [28,53,54].”
BackgroundSamson, A. C., Wells, W. M., Phillips, J. M., Hardan, A. Y., & Gross, J. J. (2015) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12370 · Cited by 115
CASE STUDY Methylphenidate Treatment of Hyperactive Autistic Children
Birmaher, B. B., Quintana, H., & Greenhill, L. L. (1988) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-198803000-00020 · Cited by 111
Emotional dysregulation in children with attention-deficit/hyperactivity disorder
van Stralen, J. (2016) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-016-0199-0 · Cited by 111
Pearson, D. A., Santos, C. W., Aman, M. G., Arnold, L. E., Casat, C. D., Mansour, R., Lane, D. M., Loveland, K. A., Bukstein, O. G., Jerger, S. W., et al. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0096 · Cited by 108 · cited 1×
“Even though the low number of individuals with intellectual disabilities in our sample did not allow us to draw conclusions about the role of intellectual disability on the effects of MPH, our findings are in accordance with previous studies [64] in which high-functioning ASD was more likely to have a favorable respon…”
ResultThe CBCL as a screen for psychiatric comorbidity in paediatric patients with ADHD
Biederman, J., Monuteaux, M. C., Kendrick, E., Klein, K. L., & Faraone, S. V. (2005) · Archives of Disease in Childhood · doi:10.1136/adc.2004.056937 · Cited by 107
Emotional dysregulation is a core component of ADHD.
Barkley, R. A. (2015) · Cited by 106
KAPLAN, S. L., BUSNER, J., KUPIETZ, S., WASSERMANN, E., & SEGAL, B. (1990) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199009000-00007 · Cited by 99
Di Martino, A., Melis, G., Cianchetti, C., & Zuddas, A. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/1044546041649011 · Cited by 82
Adult Attention-Deficit/Hyperactivity Disorder Diagnosis, Management, and Treatment in the DSM-5 Era
Young, J. L., & Goodman, D. W. (2016) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.16r02000 · Cited by 82
Biederman, J., Spencer, T., Lomedico, A., Day, H., Petty, C. R., & Faraone, S. V. (2012) · Psychological Medicine · doi:10.1017/s0033291711001644 · Cited by 78
Autism Diagnostic Observation Schedule (ADOS): Toddler Module
Luyster, R. (2013) · Springer eBooks · doi:10.1007/978-1-4419-1698-3_2011 · Cited by 75
Padilha, S. C., Virtuoso, S., Tonin, F. S., Borba, H. H. L., & Pontarolo, R. (2018) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-018-1125-0 · Cited by 73
Joshi, G., Wozniak, J. R., Fitzgerald, M., Faraone, S. V., Fried, R. S., Galdo, M., Furtak, S. L., Conroy, K., Kilcullen, J. R., Belser, A. H., et al. (2018) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-018-3542-9 · Cited by 62 · cited 2×
“Several studies analyzed the prevalence of ED both in ADHD, finding percentages between 24 and 55% in children and adolescents and 34 to 70% in adults [3,13], and in ASD, finding a percentage between 50% and 82% [5,24,25].”
BackgroundPsychopharmacology of Attention-Deficit Hyperactivity Disorder: Effects and Side Effects
Golmirzaei, J., Mahboobi, H., Yazdanparast, M. S., Mushtaq, G., Kamal, M. A., & Hamzei, E. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151124235816 · Cited by 57
Pharmacotherapy in early infantile autism.
Campbell, M. (1975) · PubMed · Cited by 52
The use of stimulant medications for non-core aspects of ADHD and in other disorders
Sinita, E., & Coghill, D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.06.014 · Cited by 51 · cited 1×
“There have been far few studies investigating the efficacy and safety of MPH in those with ADHD and co-existing disorders: some studies concluded that MPH remains effective at reducing ADHD symptoms in the presence of affective comorbidities, without an effect on comorbid conditions (anxiety, depression [36]); other s…”
BackgroundEmotion Dysregulation in Attention Deficit Hyperactivity Disorder
Shaw, P., Stringaris, A., Nigg, J., & Leibenluft, E. (2016) · Focus · doi:10.1176/appi.focus.140102 · Cited by 47
Winters, D. E., Fukui, S., Leibenluft, E., & Hulvershorn, L. A. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0124 · Cited by 47
Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis
Stuckelman, Z. D., Mulqueen, J. M., Ferracioli-Oda, E., Cohen, S. C., Coughlin, C. G., Leckman, J. F., & Bloch, M. H. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15r10601 · Cited by 42
Tsujii, N., Usami, M., Naya, N., Tsuji, T., Mishima, H., Horie, J., Fujiwara, M., & Iida, J. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00249-0 · Cited by 42
Gamlı, İ. S., & Tahiroğlu, A. Y. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s164807 · Cited by 39
Liu, L., Chen, W., Vitoratou, S., Sun, L., Yu, X., Hagger-Johnson, G., Wu, Z., Yang, L., Qian, Q., & Wang, Y. (2019) · Journal of Attention Disorders · doi:10.1177/1087054715624228 · Cited by 36
Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder
Henneberry, E. A., Lamy, M., Dominick, K. C., & Erickson, C. A. (2021) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-021-05237-9 · Cited by 32
Changes in Emotions Related to Medication Used to Treat ADHD. Part I: Literature Review
Manos, M. J., Brams, M., Childress, A. C., Findling, R. L., López, F. A., & Jensen, P. S. (2011) · Journal of Attention Disorders · doi:10.1177/1087054710381230 · Cited by 28 · cited 2×
“In ADHD individuals, preliminary evidence suggests that psychostimulants improve emotional recognition and reduce emotional lability and irritability [28].”
BackgroundMethylphenidate in Autism Spectrum Disorder: A Long-Term Follow Up Naturalistic Study
Ventura, P., de Giambattista, C., Spagnoletta, L., Trerotoli, P., Cavone, M., Gioia, A. D., & Margari, L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082566 · Cited by 28 · cited 2×
“Indeed, in our previous study, involving 80 ADHD children and adolescents of whom 40 had high-functioning ASD, long-term MPH treatment resulted in amelioration of global functioning [69].”
BackgroundSelf-citation[Emotional dysregulation and autism spectrum disorders].
Hervás, A. (2017) · PubMed · Cited by 4
Research works printed but not linked: 1
- Achenbach, T.M., and Edelbrock, C. (1983). Manual for the Child Behavior Checklist and Revised Child Behavior Profile, University of Vermont Press.
Cited by
Emotion dysregulation in autism: A meta-analysis
McDonald, R. G., Cargill, M. I., Khawar, S., & Kang, E. (2024) · Autism · doi:10.1177/13623613241257605 · Cited by 77
“…2020; Helfer et al., 2021; Lord, Gotham, et al., 2012; Mazefsky et al., 2020; Reyes et al., 2020; Samson et al., 2016, 2014; Semrud-Clikeman et al., 2010; Timko et al., 2021; Vasa et al., 2018, 2022; Ventura et al., 2022) and/or the Autism Diagnostic Interview-Revised (ADI-R; Rutter et al., 2003).”
Canals, J., Morales‐Hidalgo, P., Voltas, N., & Hernández‐Martínez, C. (2024) · Autism Research · doi:10.1002/aur.3146 · Cited by 53
“Other authors have found that impaired emotional self-regulation is more prevalent in youth with ADHD or/and autism (Bierens et al., 2023; Ventura et al., 2022) and that the shared association of these characteristics could predict social challenges (Jaisle et al., 2023).”
BackgroundGrossman, A., & Avital, A. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1118937 · Cited by 27
“, 2019), and has been shown to decrease emotional dysregulation in children with ADHD (Kutlu et al., 2017; Gamli and Tahiroglu, 2018; Ventura et al., 2022) potentially through reducing impulsivity (Gamli and Tahiroglu, 2018).”
BackgroundWang, C.-Y., & Wang, H. (2024) · All Life · doi:10.1080/26895293.2024.2415057 · Cited by 16
Relationship Between ADHD-Like Traits and Emotion Dysregulation in the Adult General Population
Albesisi, S., & Overton, P. G. (2023) · Advances in Neurodevelopmental Disorders · doi:10.1007/s41252-023-00381-y · Cited by 16
“A common underlying mechanism is also suggested by the fact that ADHD pharmacotherapies are effective against both the classical symptoms of ADHD and emotion dysregulation in ADHD (Reimherr et al., 2005; Retz et al., 2012b; Rösler et al., 2010; Ventura et al., 2022).”
Metadata
- Authors
- Ventura, P., de Giambattista, C., Trerotoli, P., Cavone, M., Di Gioia, A., & Margari, L.
- Affiliations
- University of Bari Aldo Moro (IT)
- Child Neuropsychiatric Unit, University of Bari Aldo Moro, Piazza Giulio Cesare, 70121 Bari, Italy
- Corresponding author
- Margari, Lucia
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2022-05-22
- Volume
- 11
- Issue
- 10
- Pages
- 2922
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC9142913
- OpenAlex
- W4281263944
- Semantic Scholar
- 0d5a74925aed44da48860eb9c92b379d87361749
- Cited by
- 22
- References
- 68
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 3 · 2023: 3 · 2022: 1
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
- Keywords
- methylphenidate, emotional dysregulation, attention deficit hyperactivity disorder, autism spectrum disorder, psychostimulants, children and adolescents, Child Behavior Checklist, medication effectiveness, adverse events
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.